{"id":"https://genegraph.clinicalgenome.org/r/de0881dc-f61c-4db7-a510-81290bf17a92v1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/de0881dc-f61c-4db7-a510-81290bf17a92","GCISnapshot":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-05-22T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/115f5a64-3bd7-4c56-9728-81f192493383","type":"EvidenceLine","dc:description":"Similar metabolic defects to patients were observed in this model, however there was not recapitulation of clinical phenotypes.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/68198cb7-4f3b-458f-839f-22fb2cd2ed70","type":"Finding","dc:description":"Both xav and fibroblasts from a phenotypically severe MADD patient have similar metabolic defects and mitochondrial dysfunction, including altered energy metabolism, dysregulated ROS production and altered expression of genes critical for mitochondrial function. Tandem mass spectroscopy of plasma acylcarnitine detected a markedly higher level of a spectrum of intermediate acyl-fatty acid species in xav mutants, including C4, C5, C6, C8, C14, C16 and C18, together with a drastic reduction of C2 acylcarnitine (Figure 2A), suggesting dysregulation of mitochondrial β-oxidation and alterations in multiple intermediary mitochondrial metabolic pathways in xav, similar to that observed in MADD patients. Additionally altered respiratory capacity and compensation was observed in MADD patient cells as in xav mutants.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20020044","rdfs:label":"Song 2009 Zebrafish model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c0e21107-c5ff-462c-98fe-7fb674310f16","type":"EvidenceLine","dc:description":"Similar metabolic defects to patients were observed in this model, however there was not recapitulation of clinical phenotypes.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd7b931b-6b4c-4e48-aef2-193e4b9593dd","type":"Finding","dc:description":"Embryonic accumulation of short- and medium-chain acylcarnitines (C4, C8 and C12) as well as long-chain acylcarnitines (C14 and C16:1), whose elevation is also found in severe MADD forms in humans under intense metabolic decompensation. In agreement the ETF:QO activity in the mutant embryos is markedly decreased in relation to wild type activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22580358","rdfs:label":"Alves 2012 Fruit fly model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3d1613f-9606-4961-befa-f2db1ea7c76a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e64ef3a-2235-4709-90d2-89e33db4ddd8","type":"FunctionalAlteration","dc:description":"On Western blot control fibroblast membranes had ETF-QO present while in patients 1691, 1716, and 1730 the polypeptide is absent. These three lines, and the additional patient from Gregersen et al., were also deficient in ETF-QO activity and the parents of patients 1691 and 1730 had reduced levels.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2989828","rdfs:label":"Frerman 1985 Functional Alteration"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d32bdb55-f425-4528-9733-c3c5926ea0e6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7be3d9d3-74a7-4bb5-afe6-3c3836dbac64","type":"FunctionalAlteration","dc:description":"All ETFDH variations tested compromise the ETF-QO enzyme amount and activity to various extent. At riboflavin concentrations at which wild-type ETFDH is expected to have 100% activity, the activities of variants p.Pro456Leu, p.Pro483Leu and p.Gly429Arg were 70–80% of those of wild-type. When riboflavin was moderately (28.5 nmol/l) or severely (16 nmol/l) depleted, activities of these variant ETF-QO proteins were decreased to ∼40 and 30%, respectively, of those of fully flavinylated and active wild-type protein. While p.Gly472Arg and p.Leu334Pro, did not respond significantly to changes in riboflavin concentrations, and they reached a maximum enzyme activity of only ∼5–20% of that of wild-type when cultured at supplemented riboflavin concentrations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22611163","rdfs:label":"Cornelius 2012"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7d5f0d9-493e-4567-b614-8c8375695bb4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/04e2d916-70ea-422a-a25e-128d072ad977","type":"Finding","dc:description":"The inability to oxidize fatty acids prevents the synthesis of ketone bodies, an essential alternate energy source for the heart. In such extreme cases affected individuals, who frequently die in early infancy, present with a severe, frequently fatal, metabolic acidosis that is often accompanied by a stress-induced hypertrophic cardiomyopathy and lipid accumulation in the heart, and secondary carnitine deficiency. Plays a pivotal role in supplying the energy requirements of cardiac muscle and type 1 skeletal muscle fibres.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/3620453","rdfs:label":"Frerman 1987 Biochemical","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f9cb8328-2770-467d-980e-8fbcc8931ba9_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Both missense mutations (Arg175Leu and Ala84Thr) occur at a highly conserved residues, located in FAD-binding domain, likely to change the affinity of FAD to ETF:QO and affect the electron transfer in mitochondria; supported by modeling in PMID 22013910.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c51e8b1b-f06a-4bc0-947f-695e132efd9a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19249206","rdfs:label":"Patient 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":11,"detectionMethod":"Genomic DNA was extracted from lymphocytes and all ETFDH exons (with their flanking intronic regions) were directly sequenced.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"elevated serum transaminases, Serum creatine kinase (CK) level was elevated to 1509 IU/l (normal < 269)","phenotypes":["obo:HP_0001324","obo:HP_0002015","obo:HP_0003236","obo:HP_0003546","obo:HP_0002878","obo:HP_0001733","obo:HP_0002240"],"previousTesting":true,"previousTestingDescription":"Sequence analyses of ETFA and ETFB showed no mutation","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f9cb8328-2770-467d-980e-8fbcc8931ba9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19249206","allele":[{"id":"https://genegraph.clinicalgenome.org/r/36f34983-cc91-4263-969d-da7c1c5ac609","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.524G>T (p.Arg175Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/12029"}},{"id":"https://genegraph.clinicalgenome.org/r/30b40100-7f99-419f-951f-77a090efd3e3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.250G>A (p.Ala84Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/12028"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b6e68995-b457-4bdc-920b-2058ef37eaa5_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The missense variant causes a substitution of a highly conserved Glu for Gly at position 356, putatively affecting the FAD domain of ETFDH. From PMID 22611163: c.1448C > T variant (Pro483Leu) is shown to result in significantly reduced ETFDH activity (± 30% of WT) and steady state stability (< 10% of WT) under low riboflavin conditions.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/43c763f3-3d03-493c-8013-451e6d0c3840","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29249369","rdfs:label":"Patient 3","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":23,"detectionMethod":"Next generation sequencing of candidate genes followed by Sanger sequencing to confirm potential pathogenic variants. The c.1067G>A variant is part of a homopolymeric region, and was also confirmed by RFLP.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001259","obo:HP_0003198","obo:HP_0001324","obo:HP_0001403","obo:HP_0001987","obo:HP_0002240","obo:HP_0002076","obo:HP_0001958","obo:HP_0001252"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Genotyping","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b6e68995-b457-4bdc-920b-2058ef37eaa5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29249369","allele":[{"id":"https://genegraph.clinicalgenome.org/r/ac7e2c02-8bff-4951-a43e-3204808dc091","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158699081G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358562266"}},{"id":"https://genegraph.clinicalgenome.org/r/c3edb39b-b657-4e0b-9e33-aefd76015a10","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.1448C>T (p.Pro483Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/31602"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/541708f5-5909-4e62-9617-abcf0b40a4e5_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The missense mutation (Ala84Thr) occurs at a highly conserved residue, located in FAD-binding domain, likely to change the affinity of FAD to ETF:QO and affect the electron transfer in mitochondria; supported by modeling in PMID 22013910. The frameshift mutation (c.1355delG) introduces a premature stop codon at I454X in exon 11 of ETFDH.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1de7594e-8e82-4617-bc0d-78b61898e3be","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19265687","rdfs:label":"Case 6.2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":7,"detectionMethod":"Genomic DNA was extracted from peripheral blood samples, all exons of ETFDH were amplified and sequenced in both forward and reverse directions.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"urine showed typical organic acid pattern characteristics of MADD including glutaric, 2-OH glutaric, ethylmalonic, acetoacetic, 3-OH butyric, saturated and unsaturated dicarboxylic acids, 3-OH saturated and unsaturated dicarboxylic acids and glycine conjugates","previousTesting":true,"previousTestingDescription":"To rule out mutations in other genes, phenotype segregation was studied in the families by microsatellite markers in the proximity of the 3 genes, ETFA, ETFB and ETFDH.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/541708f5-5909-4e62-9617-abcf0b40a4e5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19265687","allele":[{"id":"https://genegraph.clinicalgenome.org/r/30b40100-7f99-419f-951f-77a090efd3e3"},{"id":"https://genegraph.clinicalgenome.org/r/c992d224-babc-4215-897a-deb86acde7bb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158706258del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658795172"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c8862514-2ff9-4122-89bb-0c6ad7e25818_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The c.51dupT variant causes a frameshift (p.Ala18CysfsX5), creating a premature Stop codon. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. mRNA levels are reduced on Northern blot and protein is absent on Western blot. The missense mutation (Gln269Leu) affects a conserved amino acid, no functional evidence of impact provided.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2decd70-5ef0-47b4-9d95-7391caae6fcc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","rdfs:label":"Patient 8","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":10,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"odor of sweaty feet, affection of kidney and liver","phenotypes":["obo:HP_0001252","obo:HP_0001942","obo:HP_0001958","obo:HP_0000256"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c8862514-2ff9-4122-89bb-0c6ad7e25818_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","allele":[{"id":"https://genegraph.clinicalgenome.org/r/0f2fce19-aab4-4a31-ae23-8de75e3b609d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158695618A>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3122447"}},{"id":"https://genegraph.clinicalgenome.org/r/96251ef4-e85d-42eb-8c24-79be550d1d41","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.51dupT (p.Ala18Cysfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/195222"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/0e3f914b-d5e9-4def-9f69-8704bbd9aa8c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"From PMID 22611163 -- When expressed in HEK-293 cells this variant reached only ~40% of WT activity.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/79638356-6ce8-470c-9780-fdd7c9bc90f5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","rdfs:label":"Patient 3A","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":14,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001298","obo:HP_0001324","obo:HP_0002913"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0e3f914b-d5e9-4def-9f69-8704bbd9aa8c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","allele":{"id":"https://genegraph.clinicalgenome.org/r/2aab483c-2e60-4bed-99e1-ad8f352fbf24","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.2(ETFDH):c.1367C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/95072"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/2ae3070c-0d6e-456b-ad16-21f527079590_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This missense mutation (Arg358Ser) occurs at a highly conserved residue. Patient cells did not have ETFDH by Western blot analysis.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3f4b514-83c2-4450-a85f-083b09278b00","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","rdfs:label":"Patient 9","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":11,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001943","obo:HP_0003198","obo:HP_0002240","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2ae3070c-0d6e-456b-ad16-21f527079590_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","allele":{"id":"https://genegraph.clinicalgenome.org/r/cea28ff2-d59e-4762-b93b-a1679b5503fc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158699088G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358562293"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/413cdbcb-be32-4f02-891d-53c20a2cb7d9_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This missense variant causes a substitution of a highly conserved Glu for Gly at position 356, putatively affecting the FAD domain of ETFDH.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09ca312e-f73c-45a8-afd8-9b8370a027d1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29249369","rdfs:label":"Patient 1","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":9,"detectionMethod":"Next generation sequencing of candidate genes followed by Sanger sequencing to confirm potential pathogenic variants.","phenotypes":["obo:HP_0011994","obo:HP_0001987","obo:HP_0005164","obo:HP_0000126","obo:HP_0001642","obo:HP_0001943","obo:HP_0001511","obo:HP_0030148","obo:HP_0001942"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/413cdbcb-be32-4f02-891d-53c20a2cb7d9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29249369","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac7e2c02-8bff-4951-a43e-3204808dc091"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/3c7cc729-1fc7-4aac-ba76-86ebdc98d277_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The intronic mutation destroys the natural splice donor site of intron 3 and is expected to cause abnormal gene splicing by activating an upstream cryptic donor splice site and creating a truncated transcript by introduction of a premature stop codon predicted to be recognized by nonsense-mediated decay. All normally processed ETFDH transcripts in the patient were of the other allele, indicating total inactivation of the native donor splice site. The missense mutation (Leu138Arg) causes a non-conservative amino acid substitution, which is likely to impact secondary protein structure as a large hydrophilic amino acid arginine is substituted for the small hydrophobic leucine that is evolutionarily conserved. From PMID 22611163 -- When expressed in HEK-293 cells this variant reached only ~15% of WT activity.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/af15e169-708e-42a5-bbcb-17500dcf0763","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15669683","rdfs:label":"Olsen 2004 Patient","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over the entire coding region and subjected to direct bidirectional.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001254","obo:HP_0001943","obo:HP_0002104","obo:HP_0002240","obo:HP_0003198","obo:HP_0001252","obo:HP_0002791"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3c7cc729-1fc7-4aac-ba76-86ebdc98d277_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15669683","allele":[{"id":"https://genegraph.clinicalgenome.org/r/c6089ab9-e36a-4b4d-92e7-8e33e7564b31","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.405+3A>T","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/203730"}},{"id":"https://genegraph.clinicalgenome.org/r/17f0da31-95ce-4930-be80-8b7e11fbd8d4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.413T>G (p.Leu138Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/431962"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/68f4be9f-8313-49d2-88ea-8408c765bf3d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This missense mutation (Ser82Pro)is located in the FAD-binding domain of ETF:QO, but the affected amino acids do not make direct interactions with FAD. Predicted to affect activity, however no functional evidence provided.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/658f185d-2ebb-4611-96ff-098de1fb48a9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","rdfs:label":"Patient 2","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":7,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001328","obo:HP_0001324"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/68f4be9f-8313-49d2-88ea-8408c765bf3d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","allele":{"id":"https://genegraph.clinicalgenome.org/r/7e5a0aa2-937d-4ee4-848d-1c7ae2d3bb30","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158682263T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358574003"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/6b1c6ec3-3777-4811-a59b-6763fe9ff215_proband_score_evidence_line","type":"EvidenceLine","dc:description":"p.Ala84Thr and p.Phe128Ser mutations are most likely to alter the protein structure near the FAD binding site as well as disrupt the stability of the FAD binding required for the activation of ETF:QO using MD simulations and NMA. In turn, this instability of the FAD-binding site may impair the activity of the electron-transport system.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14276aa0-3b66-444d-8956-969ba30b10c1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22013910","rdfs:label":"Patient","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"detectionMethod":"Genomic DNA was extracted from peripheral whole blood and high-resolution melting analysis used to screen for mutation in ETFDH, the resulting samples were sequenced directly.","firstTestingMethod":"Sanger sequencing","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6b1c6ec3-3777-4811-a59b-6763fe9ff215_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22013910","allele":[{"id":"https://genegraph.clinicalgenome.org/r/30b40100-7f99-419f-951f-77a090efd3e3"},{"id":"https://genegraph.clinicalgenome.org/r/58fcb386-5272-41b0-9606-1479089430ee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.383T>C (p.Phe128Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/449387"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/35d3b245-9a3e-4822-9382-553cc40160d2_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The c.51dupT variant causes a frameshift (p.Ala18CysfsX5), creating a premature Stop codon. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The missense mutation is predicted to be deleterious. No Functional evidence provided.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14e8ee5c-dd90-4679-a60b-06552eda4ee1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","rdfs:label":"Patient 8","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":22,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0001324","previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/35d3b245-9a3e-4822-9382-553cc40160d2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","allele":[{"id":"https://genegraph.clinicalgenome.org/r/96251ef4-e85d-42eb-8c24-79be550d1d41"},{"id":"https://genegraph.clinicalgenome.org/r/68295f9b-8dd4-48c4-8f05-502a3d66750d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158685121G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3122383"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/feeb1d8b-ebe9-4573-978a-c79cb785c690_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Both missense mutations (Leu127His and Ala84Thr) occur at a highly conserved residues, located in FAD-binding domain, likely to change the affinity of FAD to ETF:QO and affect the electron transfer in mitochondria; supported by modeling in PMID 22013910.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e0ea650d-b0c4-449e-a343-3a2c2aef7bfe","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19249206","rdfs:label":"Patient 4","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":10,"detectionMethod":"Genomic DNA was extracted from lymphocytes and all ETFDH exons (with their flanking intronic regions) were directly sequenced.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"elevated venous lactate, elevation of serum transaminases levels, cardiopulmonary failure","phenotypes":["obo:HP_0003701","obo:HP_0001943","obo:HP_0003236","obo:HP_0002240","obo:HP_0001987","obo:HP_0001259","obo:HP_0001942","obo:HP_0001397"],"previousTesting":true,"previousTestingDescription":"Sequence analyses of ETFA and ETFB showed no mutation.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/feeb1d8b-ebe9-4573-978a-c79cb785c690_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19249206","allele":[{"id":"https://genegraph.clinicalgenome.org/r/30b40100-7f99-419f-951f-77a090efd3e3"},{"id":"https://genegraph.clinicalgenome.org/r/9cb9d121-7955-4703-90d7-068fc0e638fa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.380T>A (p.Leu127His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/12030"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ac2a540a-1168-4ee0-bcba-079df1057654_proband_score_evidence_line","type":"EvidenceLine","dc:description":"G467R is located at the ubiquinone-binding pocket. The change from a hydrophobic residue (glycine) to a positive charged polar residue (arginine) may have great impact on the electron transfer from ubiquinone to complex III. Er 2011 (PMID: 22013910) identified  p.Phe128Ser as altering the hydrophobic interactions between helix α1 and helix α2 and note that given the proximity of this p.Pro137Ser variant it may have similar effect.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c89a5f7-ea28-4c3d-9bf5-e2ed32fa38e8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19265687","rdfs:label":"Case 18","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"detectionMethod":"Genomic DNA was extracted from peripheral blood samples, all exons of ETFDH were amplified and sequenced in both forward and reverse directions.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0003236","obo:HP_0001252","obo:HP_0002173","obo:HP_0001958","obo:HP_0002240"],"previousTesting":true,"previousTestingDescription":"To rule out mutations in other genes, phenotype segregation was studied in the families by microsatellite markers in the proximity of the 3 genes, ETFA, ETFB and ETFDH.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ac2a540a-1168-4ee0-bcba-079df1057654_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19265687","allele":[{"id":"https://genegraph.clinicalgenome.org/r/8cb9423d-b22b-4895-8a93-96afcd4023f2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158706303G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358564495"}},{"id":"https://genegraph.clinicalgenome.org/r/9fb39a31-52cd-4774-b25f-07c0da0826e6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158684595C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA501142"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/229b17fe-82a9-468b-90d9-b36176323cf9_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This missense mutation (Arg175Leu) occurs at a highly conserved residue, located in FAD-binding domain, likely to change the affinity of FAD to ETF:QO and affect the electron transfer in mitochondria; supported by modeling in PMID 22013910.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0560c8e7-a9b6-40c5-9d5b-09eab8a5ac0c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19249206","rdfs:label":"Patient 3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":19,"detectionMethod":"Genomic DNA was extracted from lymphocytes and all ETFDH exons (with their flanking intronic regions) were directly sequenced.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002421","obo:HP_0002015","obo:HP_0003691","obo:HP_0003307","obo:HP_0003690","obo:HP_0003236","obo:HP_0003546","obo:HP_0001284"],"previousTesting":true,"previousTestingDescription":"Sequence analyses of ETFA and ETFB showed no mutation.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/229b17fe-82a9-468b-90d9-b36176323cf9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19249206","allele":{"id":"https://genegraph.clinicalgenome.org/r/30b40100-7f99-419f-951f-77a090efd3e3"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/062e336e-cfda-45f7-b509-cd44a5079034_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0fa9e87-a62a-4281-8cc9-878d6e54c70e_proband_segregation","type":"FamilyCosegregation","dc:description":"Too few segregations to include.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19249206","rdfs:label":"Sisters 1 and 2","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/c0fa9e87-a62a-4281-8cc9-878d6e54c70e","type":"Family","rdfs:label":"Sisters 1 and 2","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/c51e8b1b-f06a-4bc0-947f-695e132efd9a"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0001324","proband":{"id":"https://genegraph.clinicalgenome.org/r/c51e8b1b-f06a-4bc0-947f-695e132efd9a"}},{"id":"https://genegraph.clinicalgenome.org/r/875db997-ebcb-41f7-a469-d11aa247df21_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","rdfs:label":"Family 3","family":{"id":"https://genegraph.clinicalgenome.org/r/875db997-ebcb-41f7-a469-d11aa247df21","type":"Family","rdfs:label":"Family 3","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/79638356-6ce8-470c-9780-fdd7c9bc90f5"}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/79638356-6ce8-470c-9780-fdd7c9bc90f5"}},{"id":"https://genegraph.clinicalgenome.org/r/6556831b-e337-4057-974d-0cc79ed8432d_proband_segregation","type":"FamilyCosegregation","dc:description":"Too few segregations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19265687","rdfs:label":"Family 2","estimatedLodScore":0.85,"family":{"id":"https://genegraph.clinicalgenome.org/r/6556831b-e337-4057-974d-0cc79ed8432d","type":"Family","rdfs:label":"Family 2","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/4c89a5f7-ea28-4c3d-9bf5-e2ed32fa38e8"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/4c89a5f7-ea28-4c3d-9bf5-e2ed32fa38e8"}},{"id":"https://genegraph.clinicalgenome.org/r/017d020c-70c6-4916-b794-c6a68c57e8e9_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","rdfs:label":"Family 4","family":{"id":"https://genegraph.clinicalgenome.org/r/017d020c-70c6-4916-b794-c6a68c57e8e9","type":"Family","rdfs:label":"Family 4","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/74b93fd4-3f4e-4232-900e-2fde22c82638","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","rdfs:label":"Patient 4A","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":16,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002013","obo:HP_0001298"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/59bb1cd6-4a09-4ab8-8e97-d1db3fafcb6b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","allele":{"id":"https://genegraph.clinicalgenome.org/r/58d07812-705e-48f3-9d5c-675fe666394b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158706254G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312543"}}}}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002013","obo:HP_0001298"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/74b93fd4-3f4e-4232-900e-2fde22c82638"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f4f078ad-068c-4752-bfcc-ed399a6a7a6f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"c.158A>G variation, which was predicted to be a benign missense variation (Lys53Arg), instead causes exon 2 skipping (demonstrated in patient cells and a splicing reporter minigene) and ETFDH protein degradation (evidenced by decreased quantity in patient cells by Western blot). We show that the c.158A>G variation increases the affinity of existing binding sites for hnRNP A1 and hnRNP A2/B1 and creates a new hnRNP H-binding site (exonic splicing silencer sites). The increased binding of these splicing inhibitory proteins abolishes binding of the splicing stimulatory proteins SRSF1 and SRSF5 (shown by pull-down).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4ce2ab8-e538-4003-bb70-78d87e55edbc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24123825","rdfs:label":"Patient","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":2,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over the entire coding region and subjected to direct bidirectional.","firstTestingMethod":"Sanger sequencing","previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/f4f078ad-068c-4752-bfcc-ed399a6a7a6f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24123825","allele":{"id":"https://genegraph.clinicalgenome.org/r/1be29ded-b08c-4d5c-a85b-6b2eee8ff4ca","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158680590A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358573551"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d74b4eb8-d781-49c9-b312-285f5ca762a8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This missense mutation (Gly472Arg) replaces a highly conserved glycine with an arginine, a moderate physicochemical difference. From PMID 22611163 -- When expressed in HEK-293 cells this variant reached only ~5-20% of WT activity.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f15cba4c-9417-436f-ab5a-5c18767df9d4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","rdfs:label":"Patient 5","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":3,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001943","obo:HP_0001252","obo:HP_0002104","obo:HP_0001942","obo:HP_0003811","obo:HP_0001397","obo:HP_0000961"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d74b4eb8-d781-49c9-b312-285f5ca762a8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","allele":{"id":"https://genegraph.clinicalgenome.org/r/553546b6-4ff5-432b-b3aa-593658be5dd0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004453.3(ETFDH):c.1414G>A (p.Gly472Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/459963"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a8930352-639e-478b-a936-15bd5eb96036_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The c.36del creates Ala12fs with generates a premature stop codon at position 19 resulting in no predicted stable ETFDH. Patient cells did not have ETFDH by Western blot analysis.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/58d0962d-1de4-4f24-91f9-995d59010f82","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","rdfs:label":"Patient 1","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":1,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001397","obo:HP_0002098","obo:HP_0006693","obo:HP_0002089","obo:HP_0002009","obo:HP_0007033","obo:HP_0000113","obo:HP_0001396","obo:HP_0003811"],"previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/a8930352-639e-478b-a936-15bd5eb96036_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","allele":{"id":"https://genegraph.clinicalgenome.org/r/2661cc6c-ba02-40c6-911f-3534a552e159","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"ETFDH, 1-BP DEL, 36A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/12027"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/59bb1cd6-4a09-4ab8-8e97-d1db3fafcb6b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence provided.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/74b93fd4-3f4e-4232-900e-2fde22c82638"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/cc05bb45-9637-415c-9757-952ef4a406d1_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The missense variant (Val451Leu) is predicted to be deleterious. The nonsense variant (Glu354Ter)  introduces a premature stop codon in exon 9: RT-PCR studies revealed that no normally processed ETFDH transcript is produced from the allele with this mutation; the c.1060G>T mutation seems mainly to cause nonsense-mediated mRNA decay of the corresponding transcripts (Garneau et al., 2007) and to a minor degree to cause skipping of exon 9.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6d90a624-f645-46f4-82c9-14d428fd8793","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","rdfs:label":"Patient 10","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":26,"detectionMethod":"cDNA was prepared from total RNA of patient fibroblasts, amplified over 5 overlapping fragments and subjected to direct bidirectional cycle sequencing. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0001324","previousTesting":true,"previousTestingDescription":"ETFA and ETFB were sequenced for causative variants.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/cc05bb45-9637-415c-9757-952ef4a406d1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17584774","allele":[{"id":"https://genegraph.clinicalgenome.org/r/58d07812-705e-48f3-9d5c-675fe666394b"},{"id":"https://genegraph.clinicalgenome.org/r/a449e06d-fd3b-43d0-99f2-8109af308a94","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000004.12:g.158699074G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358562233"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":403,"specifiedBy":"GeneValidityCriteria6","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Hhp3BSxSorQ","type":"GeneValidityProposition","disease":"obo:MONDO_0009282","gene":"hgnc:3483","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_062e336e-cfda-45f7-b509-cd44a5079034-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}